Profiles
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles
- CT Atherosclerosis Biomarkers 2023-03-28
- CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18
- CT Tumor Volume Change for Advanced Disease 2022-07-21 - Streamlined Profile including Conformance Checklists
Stage 2: Consensus Profiles
- CT Lung Density 2020-09-04 (Contains Conformance Checklists, Appendix B) 2020-10-23
Stage 1: Public Comment Profiles
Please submit comments using the online form
- MR DCE Quantification 2020-10-12 (comments closed on March 10, 2021)
- fMRI for Sensorimotor Mapping 2017-06-19 (comments closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Tools to aid Biomarker Committees in collating these comments:
- {Public Comment Resolution} - Editor collates all comments into a resolution spreadsheet (see Google Sheet template)
- {Site responses for Stage 3} - Field Test Leader collates all Feedback comments into a Feedback Resolution spreadsheet
QIBA Profiles and Clinical Applications
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)